Your browser is no longer supported. Please, upgrade your browser.
Settings
SNGX [NASD]
Soligenix, Inc.
Index- P/E- EPS (ttm)-0.38 Insider Own0.15% Shs Outstand40.70M Perf Week-10.52%
Market Cap32.66M Forward P/E- EPS next Y-0.48 Insider Trans0.00% Shs Float40.00M Perf Month-21.78%
Income-13.40M PEG- EPS next Q-0.09 Inst Own11.20% Short Float2.52% Perf Quarter-28.24%
Sales0.90M P/S36.29 EPS this Y-33.30% Inst Trans-0.68% Short Ratio0.58 Perf Half Y-30.16%
Book/sh0.37 P/B2.11 EPS next Y-15.00% ROA-48.30% Target Price4.88 Perf Year-68.71%
Cash/sh0.69 P/C1.13 EPS next 5Y1.00% ROE-103.60% 52W Range0.75 - 2.80 Perf YTD-38.89%
Dividend- P/FCF- EPS past 5Y26.50% ROI-126.80% 52W High-72.06% Beta1.24
Dividend %- Quick Ratio6.10 Sales past 5Y-23.10% Gross Margin15.50% 52W Low4.29% ATR0.06
Employees17 Current Ratio6.10 Sales Q/Q-66.70% Oper. Margin- RSI (14)30.69 Volatility9.35% 6.85%
OptionableNo Debt/Eq0.65 EPS Q/Q-45.60% Profit Margin- Rel Volume0.17 Prev Close0.80
ShortableYes LT Debt/Eq0.65 Earnings- Payout- Avg Volume1.74M Price0.78
Recom2.50 SMA20-12.01% SMA50-19.66% SMA200-32.59% Volume302,288 Change-2.23%
Jul-28-20Downgrade Dawson James Buy → Neutral
Jan-31-18Downgrade H.C. Wainwright Buy → Neutral $5.50 → $2.70
Aug-14-17Reiterated Maxim Group Buy $4 → $5
Jul-17-17Initiated H.C. Wainwright Buy $11
Dec-02-21 07:30AM  
Nov-30-21 08:30AM  
Nov-22-21 04:23AM  
Nov-12-21 07:30AM  
Nov-08-21 07:30AM  
Nov-04-21 07:30AM  
Nov-01-21 07:30AM  
Oct-13-21 08:30AM  
Oct-12-21 07:30AM  
Oct-07-21 08:30AM  
Sep-29-21 08:21AM  
Sep-28-21 07:30AM  
Sep-27-21 07:30AM  
Sep-16-21 01:14PM  
07:30AM  
Sep-14-21 08:30AM  
Sep-13-21 12:31PM  
Sep-09-21 07:30AM  
Aug-24-21 08:30AM  
Aug-23-21 07:30AM  
Aug-19-21 05:30AM  
Aug-18-21 11:41AM  
08:52AM  
Aug-13-21 07:30AM  
Jul-29-21 08:30AM  
Jul-22-21 08:30AM  
Jul-08-21 11:20AM  
Jul-06-21 03:39PM  
08:30AM  
Jun-23-21 09:35AM  
Jun-22-21 07:30AM  
Jun-10-21 07:30AM  
Jun-09-21 07:30AM  
Jun-03-21 08:30AM  
May-24-21 07:50AM  
May-20-21 07:30AM  
May-17-21 07:30AM  
07:00AM  
07:00AM  
May-10-21 08:39AM  
07:30AM  
May-04-21 07:30AM  
Apr-28-21 07:30AM  
Apr-26-21 07:00AM  
Apr-13-21 07:00AM  
Apr-07-21 07:00AM  
Mar-31-21 12:30PM  
Mar-30-21 07:00AM  
Mar-16-21 08:30AM  
05:52AM  
Mar-09-21 07:00AM  
Mar-04-21 08:12AM  
07:00AM  
Feb-24-21 07:00AM  
Feb-23-21 08:30AM  
Feb-11-21 07:00AM  
Feb-09-21 08:30AM  
Feb-01-21 07:00AM  
Jan-28-21 06:51AM  
Jan-25-21 08:30AM  
Jan-19-21 07:00AM  
Jan-07-21 07:00AM  
Dec-28-20 07:00AM  
Dec-23-20 04:50AM  
Dec-22-20 07:45AM  
06:30AM  
Dec-16-20 09:00AM  
Dec-08-20 08:00AM  
Nov-17-20 08:00AM  
Nov-16-20 06:12AM  
05:25AM  
Nov-12-20 08:46AM  
07:40AM  
07:00AM  
Nov-10-20 07:00AM  
Oct-23-20 05:40AM  
Oct-22-20 10:40AM  
09:00AM  
Oct-08-20 09:40AM  
Sep-21-20 08:30AM  
Sep-15-20 07:30AM  
Sep-11-20 09:41AM  
Sep-10-20 07:30AM  
Sep-09-20 07:00AM  
Sep-03-20 03:18PM  
07:30AM  
Aug-27-20 07:00AM  
Aug-17-20 09:10AM  
Aug-14-20 07:00AM  
Aug-12-20 02:15PM  
Jul-28-20 07:00AM  
Jul-20-20 07:00AM  
Jun-30-20 07:00AM  
Jun-26-20 02:53PM  
06:32AM  
Jun-24-20 07:00AM  
Jun-22-20 07:00AM  
05:39AM  
Jun-09-20 07:00AM  
May-28-20 03:28PM  
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate, which has completed Phase I/II clinical trial for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease and SGX201 for acute radiation enteritis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ZELDIS JEROME BDirectorMay 14Buy0.893,0002,66425,917May 18 05:00 PM
ZELDIS JEROME BDirectorMay 14Sale0.903,0002,70122,917May 18 05:00 PM